US Federal Circuit Pauses Teva, Apotex After Hetlioz Patent Win
Vanda’s Tasimelteon Molecule Patent Expired ‘Just Last Week’
Executive Summary
Teva and Apotex must put their plans to launch generic versions of Vanda’s Hetlioz on ice after the originator was granted – for now – a small injunction against the ANDA sponsors.
You may also be interested in...
What’s Next? Five Things To Look Out For In August
Generics Bulletin previews the most notable and anticipated events for August 2023.
Vanda’s Fourth Suit Against US FDA Claims Agency Shared Its Manufacturing Trade Secrets
Vanda is fighting FDA’s rejection of jet lag indication for Hetlioz as it faces generic competition for sleep-wake disorder treatment. Federal Circuit finds four Hetlioz patents invalid.
Absence Of Braille In Generic Hetlioz Label Merits Its Withdrawal, Vanda Lawsuit Argues
Vanda complaint against US FDA says generic label is not the same as Hetlioz and omission of braille lettering will increase medication errors. Company seeks recall of Teva’s product.